On Friday, Shares of Transocean Ltd. (NYSE:RIG), lost -1.95% to $13.57.
Transocean stated net income attributable to controlling interest of $342 million, $0.93 per diluted share, for the three months ended June 30, 2015.
For the three months ended June 30, 2014, the company stated both net income attributable to controlling interest and adjusted net income of $587 million, or $1.61 per diluted share.
Revenues for the three months ended June 30, 2015 reduced $159 million sequentially to $1.884 billion due primarily to lower utilization partly offset by higher revenue efficiency.
Not taking into account $788 million ($735 million after taxes) in net favorable items associated with Macondo-related insurance proceeds, reimbursement of legal fees, crew claims and other contingent liability adjustments, operating and maintenance expenses were $985 million. This compares with $1.084 billion in the preceding quarter. The decrease of $99 million was due primarily to reduced activity mainly related to rig retirements, stacked and idle rigs, and the company`s ongoing cost reduction initiatives.
Transocean Ltd., together with its auxiliaries, provides offshore contract drilling services for oil and gas wells worldwide. The company primarily offers deepwater and harsh environment drilling services.
Shares of Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), declined -9.12% to $4.98, during its last trading session.
Pernix Therapeutics Holdings declared financial results for the second quarter ended June 30, 2015.
Financial Results -Second Quarter 2015
For the second quarter of 2015, net revenues were $47.0 million, an enhance of $29.6 million, or 151%, as compared to $17.4 million for the second quarter of 2014.
The company recorded no manufacturing revenue during the second quarter of 2015 contrast with $154,000 for the same period in 2014, due to the sale of our manufacturing partner PML in April 2014. Co-promotion and other revenue reduced by $490,000 to $223,000 due to the Natroba co-promotion agreement termination.
Gross profit margin as a percentage of net revenues was 71% as compared to 46% in the second quarter of 2014, not taking into account the impact of attained inventory step up. The enhance was primarily due to the Treximet and Zohydro ER launches. Cost of product sales will enhance with Silenor, Treximet, and Zohydro ER sales growth, in addition to associated higher royalty expenses.
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells branded and generic pharmaceutical products.
Finally, E. I. du Pont de Nemours and Company (NYSE:DD), ended its last trade with -1.91% loss, and closed at $53.43.
DuPont officially opened its Integrated Seed Science Center in Johnston, Iowa. This is the second facility in the DuPont Integrated Seed Science Network that is dedicated to developing and testing seed treatment formulations, applications and seed handling techniques. The Johnston center features experts and equipment that assist DuPont deliver the right seed treatments for growers’ fields to optimize genetic performance of seeds.
Aimed at ensuring growers get the most out the seeds they plant, the Integrated Seed Science Center brings together a wide array of equipment, technology and training resources, counting:
- Laboratories to evaluate the right combination of seed-applied products to assist protect the seed and optimize yield potential.
- Treating and drying testing to better understand how components and processes interact which delivers a higher quality assurance and enhances product stewardship.
- Real-world testing conditions for products and equipment.
- Plantability evaluations that check for accuracy through planter meters and seed flow, essential for modern day planters.
- Training lab to facilitate superior seed application and seed handling techniques to ensure a compriseent grower experience with treated seed.
E.I. du Pont de Nemours and Company operates as a science and technology based company worldwide. The company’s Agriculture segment offers corn hybrid, soybean, canola, sunflower, sorghum, inoculants, seed products, wheat, rice, herbicides, fungicides, and insecticides.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
